Update DEA Hearing July 6: Harvard Expert Testifies State Dispensary Cannabis Does Not Meet Pharmaceutical Standards

MMJ International Holdings has challenged the Department of Justice’s position regarding the standing of pharmaceutical companies in the federal cannabis rescheduling process. During a recent Drug Enforcement Administration hearing, Harvard expert Dr. Bertha Madras testified that cannabis products sold through state dispensaries fail to meet the rigorous pharmaceutical standards required for FDA-approved medicines. This legal and regulatory conflict highlights the significant hurdles faced by biotech firms attempting to navigate the traditional federal drug development pathway while state-level markets operate under different criteria.

MMJ International Holdings (MMJIH) and its subsidiaries, MMJ BioPharma Cultivation and MMJ BioPharma Labs, have responded to a Department of Justice (DOJ) filing in the U.S. Court of Appeals for the District of Columbia Circuit regarding the federal rescheduling of marijuana. The company, which has spent eight years pursuing the FDA’s pharmaceutical development pathway for cannabinoid medicines, argues that the government is dismissing its efforts as a mere "pocketbook interest." MMJ CEO Duane Boise emphasized that the firm has established a DEA Schedule I analytical laboratory and filed a bulk manufacturing application in 2018 to support research into treatments for Huntington’s disease and multiple sclerosis.

The legal conflict centers on the DOJ's claim that MMJ lacks competitor standing because it does not yet have an FDA-approved product on the market. MMJ counters that the primary obstacle to approval is the DEA’s failure to resolve its bulk manufacturing registration, which has been pending for nearly eight years. Boise argued that the government cannot require companies to follow a rigorous scientific pathway and then use the resulting regulatory delays to deny them legal standing. The company asserts that its investigational medicines have already been characterized and submitted to the FDA, but the lack of a cultivation license prevents the necessary clinical trials from proceeding.

During a related DEA administrative hearing, Harvard Medical School professor Dr. Bertha Madras testified that products sold through state marijuana dispensaries generally fail to meet the pharmaceutical standards required for legitimate medicine. Dr. Madras highlighted the necessity of randomized, double-blind clinical trials and expressed concerns regarding inconsistent product composition and contaminant controls in state-regulated markets. MMJ representatives noted that the Administrative Law Judge overruled several objections to this testimony, allowing Dr. Madras to detail the importance of batch-to-batch consistency and validated manufacturing. The company maintains that the federal government must apply a consistent scientific standard to all entities seeking to develop cannabinoid-based therapies to protect public health and scientific integrity.